Literature DB >> 3855433

Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow.

F M Uckun, S Ramakrishnan, L L Houston.   

Abstract

An immunotoxin was synthesized with pokeweed antiviral protein and an IgG1 monoclonal antibody directed against human B and pre-B cells. The B43 murine monoclonal antibody does not react with normal human bone marrow precursor cells. The immunotoxin bound to all Burkitt's lymphoma cell lines that were tested but not to human peripheral blood T cells. The ability of antibody-toxin conjugate to inhibit human lymphoblast cell lines was checked in a clonogenic assay system. The immunotoxin in the presence of chloroquine elicited 5.8 logs of killing of Burkitt's lymphoma cells (B-ALL). The efficient inhibition of clonogenic growth of B-ALL cells was not affected by the presence of normal bone marrow cells. The immunotoxin was not very toxic to pluripotent stem cells; less than 50% of the stem cells were lost under conditions where 5.6 logs of clonogenic lymphoma cells were eliminated from a 100-fold excess of normal marrow cells. Further, when assayed by long-term human bone marrow cultures, immunotoxin treatment did not result in a significant loss of pluripotent precursor cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3855433

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and saporin 6: effect on T lymphocytes and hemopoietic cells.

Authors:  P L Tazzari; L Barbieri; M Gobbi; A Dinota; S Rizzi; A Bontadini; A Pession; S Tura; F Stirpe
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 2.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma.

Authors:  K S Webb; S N Liberman; J L Ware; P J Walther
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Ex vivo elimination of neoplastic T-cells from human marrow using an anti-Mr 41,000 protein immunotoxin: potentiation by ASTA Z 7557.

Authors:  F M Uckun; S Ramakrishnan; L L Houston
Journal:  Blut       Date:  1985-01

Review 5.  Monoclonal antibodies--therapeutic and diagnostic uses in malignancy.

Authors:  J N Lowder; R Levy
Journal:  West J Med       Date:  1985-12

Review 6.  Chemical construction of immunotoxins.

Authors:  V Ghetie; E S Vitetta
Journal:  Mol Biotechnol       Date:  2001-07       Impact factor: 2.860

7.  An immunotoxin containing momordin suitable for bone marrow purging in multiple myeloma patients.

Authors:  A Dinota; L Barbieri; M Gobbi; P L Tazzari; S Rizzi; A Bontadini; A Bolognesi; S Tura; F Stirpe
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

8.  Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia.

Authors:  F M Uckun; K J Gajl-Peczalska; J H Kersey; L L Houston; D A Vallera
Journal:  J Exp Med       Date:  1986-02-01       Impact factor: 14.307

Review 9.  Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers.

Authors:  Hendrik Fuchs; Alexander Weng; Roger Gilabert-Oriol
Journal:  Toxins (Basel)       Date:  2016-07-01       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.